[go: up one dir, main page]

AP2012006258A0 - Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens. - Google Patents

Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.

Info

Publication number
AP2012006258A0
AP2012006258A0 AP2012006258A AP2012006258A AP2012006258A0 AP 2012006258 A0 AP2012006258 A0 AP 2012006258A0 AP 2012006258 A AP2012006258 A AP 2012006258A AP 2012006258 A AP2012006258 A AP 2012006258A AP 2012006258 A0 AP2012006258 A0 AP 2012006258A0
Authority
AP
ARIPO
Prior art keywords
gag
immune responses
hiv env
recombinant mva
viruses expressing
Prior art date
Application number
AP2012006258A
Other languages
English (en)
Inventor
Harriet L Robinson
Bernard Moss
Linda S Wyatt
Original Assignee
Geovax Inc
Univ Emory
Us Gov Nat Inst Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geovax Inc, Univ Emory, Us Gov Nat Inst Health filed Critical Geovax Inc
Publication of AP2012006258A0 publication Critical patent/AP2012006258A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AP2012006258A 2009-10-13 2010-10-13 Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens. AP2012006258A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25111909P 2009-10-13 2009-10-13
PCT/US2010/052484 WO2011047031A2 (en) 2009-10-13 2010-10-13 Eliciting immune responses using recombinant mva viruses expressing hiv env, gag and pol anitgens

Publications (1)

Publication Number Publication Date
AP2012006258A0 true AP2012006258A0 (en) 2012-06-30

Family

ID=43876843

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006258A AP2012006258A0 (en) 2009-10-13 2010-10-13 Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.

Country Status (2)

Country Link
AP (1) AP2012006258A0 (xx)
WO (1) WO2011047031A2 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009946A1 (en) * 2013-07-17 2015-01-22 Emory University Method of increasing immune response to hiv antigens
AU2017206102C1 (en) 2016-01-08 2022-02-10 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
US11052148B2 (en) 2016-05-30 2021-07-06 Geo Vax, Inc. Compositions and methods for generating an immune response to hepatitis B virus
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
WO2025133250A1 (en) * 2023-12-21 2025-06-26 Universitat Pompeu Fabra Pseudotyped viral like particle for immune cells transduction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4088697A (en) * 1996-08-26 1998-03-19 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
DE60234018D1 (de) * 2001-03-08 2009-11-26 Univ Emory Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene
WO2006026667A2 (en) * 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
ES2281252B1 (es) * 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.

Also Published As

Publication number Publication date
WO2011047031A3 (en) 2011-09-22
WO2011047031A2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
WO2013085550A3 (en) V1v2 immunogens
IL210162A0 (en) Viral inactivated platelet extract, use and preparation thereof
AP2011005541A0 (en) HIV vaccine based on targeting maximized GAG and NEF to dendritic cells.
SMT201800016T1 (it) Anticorpi neutralizzanti il virus dell'immunodeficenza umana (hiv)
SI3556396T1 (sl) Nevtralizacijska protitelesa proti virusu človeške imunske pomanjkljivosti (HIV)
IL239805A0 (en) Trimer vaccines with a stabilized HIV envelope
WO2011103417A3 (en) Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
ZA201307529B (en) Truncated hiv envelope proteins (env), methods and compositions related thereto
PH12013502322A1 (en) Hendra and nipah virus g glycoprotein immunogenic compositions
HK1213478A1 (zh) 鱼用亚单位浸泡疫苗
WO2012047267A3 (en) Polyvalent immunogen
WO2009115917A3 (en) Improvements in preparation of influenza virus vaccine antigens
EA201290956A1 (ru) Вакцина против вич
AP2012006258A0 (en) Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.
IN2014KN02740A (xx)
WO2013052095A3 (en) Vaccine
WO2008033500A3 (en) Carbohydrate-based vaccines for hiv
ECSP12012131A (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quiméricos
WO2013046034A3 (en) Use of non-subtype b gag proteins for lentiviral packaging
WO2010040572A3 (en) Antibodies against h5n1 influenza viruses
WO2005110492A3 (en) Method of using adenoviral vectors to induce an immune response
WO2010040136A3 (en) Selection of hiv vaccine antigens by use of intrapatient sequence variation to identify mutations in the hiv envelope glycoprotein that affect the binding of broadly neutralizing antibodies
AP2011005853A0 (en) Splitting GP41.
PL2643460T3 (pl) Sposoby, kompozycje i zestawy do oznaczania ludzkiego wirusa niedoboru odporności (HIV)